Less good results from a trial reporting last year:
"In this 6-month, multicenter, randomized placebo-controlled clinical trial of 76 participants with moderately advanced PD, nilotinib at 150-mg and 300-mg daily doses met prespecified safety and tolerability criteria. There was no evidence of symptomatic benefit of nilotinib on any measures of PD disability and there was trend toward worsening in the motor function in active treatment arms;"
"Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease
A Randomized Clinical Trial"
Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial | Movement Disorders | JAMA Neurology | JAMA Network
John